Top

Published in:

01-02-2017 | Original Article

HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)

Authors: Francesco Soria, Marco Moschini, Andrea Haitel, Gregory J. Wirth, Jose A. Karam, Christopher G. Wood, Morgan Rouprêt, Vitaly Margulis, Pierre I. Karakiewicz, Alberto Briganti, Jay D. Raman, Solene-Florence Kammerer-Jacquet, Romain Mathieu, Karim Bensalah, Yair Lotan, Mehmet Özsoy, Mesut Remzi, Kilian M. Gust, Shahrokh F. Shariat

Published in: World Journal of Urology | Issue 2/2017

Abstract

Purpose

The aim of our study was to evaluate the expression pattern of HER2 overexpression in patients with upper tract urothelial carcinoma (UTUC) and to evaluate its association with clinical outcomes.

Methods

This multicenter retrospective study included 732 patients treated with radical nephroureterectomy for UTUC. HER2 expression was assessed using immunohistochemistry and scored according to the HercepTest: Scores of 0 or 1 were considered negative and 2 or 3 as positive. To qualify for 2 scoring, complete membrane staining of more than 10 % of tumor cells at a moderate intensity had to be observed.

Results

HER2 was overexpressed in 262 (35.8 %) patients. It was associated with pathologic characteristics such as more advanced T stage (p < 0.001), presence of lymph node metastasis (p = 0.006), high-grade tumor (p < 0.001), tumor necrosis (p = 0.01) and lymphovascular invasion (p = 0.02). Patients with HER2 overexpression had a 1.66-fold increased risk of experiencing disease recurrence (95 % CI 1.24–2.24, p = 0.001), 1.55-fold increased risk of death (95 % CI 1.21–1.99, p = 0.001) and 1.81-fold increased risk of cancer-specific death (95 % CI 1.33–2.48, p < 0.001). On multivariable analysis that adjusted for the effects of standard clinicopathologic variables, HER2 overexpression remained associated with disease recurrence (p = 0.04), overall (p = 0.02) and cancer-specific mortality (p = 0.02).

Conclusions

Approximately, one-third of UTUC patients overexpressed HER2. HER2 overexpression was associated with features of clinically and biologically aggressive disease as well as prognosis. HER2 may represent a good marker for therapeutic risk stratification and potentially a target for therapy in some UTUC tumors.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2016. CA Cancer J Clin. doi:10.3322/caac.21332

Abouassaly R, Alibhai SMH, Shah N, Timilshina N, Fleshner N, Finelli A (2010) Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 76:895–901. doi:10.1016/j.urology.2010.04.020 CrossRefPubMed

Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M et al (2015) European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68:868–879. doi:10.1016/j.eururo.2015.06.044 CrossRefPubMed

Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233. doi:10.1002/cncr.24135 CrossRefPubMed

Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS et al (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61:818–825. doi:10.1016/j.eururo.2012.01.021 CrossRefPubMed

Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR et al (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 189:1662–1669. doi:10.1016/j.juro.2012.10.057 CrossRefPubMed

Jeldres C, Sun M, Lughezzani G, Isbarn H, Shariat SF, Widmer H et al (2010) Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer 116:3774–3784. doi:10.1002/cncr.25122 CrossRefPubMed

Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI et al (2015) The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU Int 116:72–78. doi:10.1111/bju.12801 CrossRefPubMed

Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the upper tract urothelial carcinoma collaboration. J Urol 182:900–906. doi:10.1016/j.juro.2009.05.011 CrossRefPubMed

10.

Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L et al (2014) Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int 114:733–740. doi:10.1111/bju.12631 CrossRefPubMed

11.

Fritsche H-M, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300–309. doi:10.1016/j.eururo.2009.09.024 CrossRefPubMed

12.

Xylinas E, Kluth L, Passoni N, Trinh Q-D, Rieken M, Lee RK et al (2014) Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 65:650–658. doi:10.1016/j.eururo.2013.09.003 CrossRefPubMed

13.

Sasaki Y, Sasaki T, Kawai T, Morikawa T, Matsusaka K, Kunita A et al (2014) HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. Int J Clin Exp Pathol 7:699–708PubMedPubMedCentral

14.

Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A (2001) HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2):67–72CrossRefPubMed

15.

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R (2015) HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 34:157–164. doi:10.1007/s10555-015-9552-6 CrossRefPubMedPubMedCentral

16.

Bianchini G, Gianni L (2014) The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 15:e58–e68. doi:10.1016/S1470-2045(13)70477-7 CrossRefPubMed

17.

Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) 376:687–697. doi:10.1016/S0140-6736(10)61121-X CrossRef

18.

Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M et al (2015) HER2 as a target in invasive urothelial carcinoma. Cancer Med 4:844–852. doi:10.1002/cam4.432 CrossRefPubMedPubMedCentral

19.

Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI et al (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 106:1216–1222. doi:10.1111/j.1464-410X.2009.09190.x CrossRefPubMed

20.

Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J et al (2011) ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS ONE 6:e27616. doi:10.1371/journal.pone.0027616 CrossRefPubMedPubMedCentral

21.

Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S et al (2015) Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer. J Urol 194:1120–1131. doi:10.1016/j.juro.2015.05.087 CrossRefPubMed

22.

Tsai YS, Tzai TS, Chow NH, Wu CL (2005) Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology 66:1197–1202. doi:10.1016/j.urology.2005.06.117 CrossRefPubMed

23.

Vershasselt-Crinquette M, Colin P, Ouzzane A, Gnemmi V, Robin Y-M, Aubert S et al (2015) HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. J Urol 66:2439–2445. doi:10.1097/PAI.0b013e318241cab9

24.

Izquierdo L, Truan D, Mengual L, Mallofre C, Alcaraz A (2010) HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res 30:2439–2445PubMed

25.

Sobin LH, Gospodarowicz MK, Wittekind Ch (2009) TNM classification of malignant tumours, vol 10. doi:10.1016/S0936-6555(98)80120-9

26.

Montironi R, Lopez-Beltran A (2005) The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 13:143–153CrossRefPubMed

27.

Chromecki T, Bensalah K, Remzi M, Verhoest G, Cha EK (2011) Prognostic factors for upper urinary tract urothelial carcinoma. PubMed–NCBI. Nat Rev Urol 440–447. http://www-ncbi-nlm-nih-gov.offcampus.dam.unito.it/pubmed/21727942. Accessed 5 Apr 2016

28.

Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A et al (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57:575–581. doi:10.1016/j.eururo.2009.11.035 CrossRefPubMed

29.

Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402–1412. doi:10.1111/j.1464-410X.2010.09217.x CrossRefPubMed

30.

Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889–1897. doi:10.1016/j.ejca.2013.02.001 CrossRefPubMed

31.

Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61:854–855. doi:10.1016/j.eururo.2011.12.055 CrossRefPubMed

32.

Vershasselt-Crinquette M, Colin P, Ouzzane A, Gnemmi V, Robin Y-M, Aubert S et al (2012) Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry. Appl Immunohistochem Mol Morphol 20:363–366. doi:10.1097/PAI.0b013e318241cab9 CrossRefPubMed

33.

Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (London, England) 382:1021–1028. doi:10.1016/S0140-6736(13)61094-6 CrossRef

34.

Xylinas E, Kluth L, Mangal S, Roupret M, Karakiewicz PI, Shariat SF (2013) Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. World J Urol 31:31–36. doi:10.1007/s00345-012-0947-5 CrossRefPubMed

35.

Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601–1609. doi:10.1016/j.eururo.2007.09.036 CrossRefPubMed

36.

Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos M-A et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117:5500–5508. doi:10.1002/cncr.26172 CrossRefPubMed

37.

Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529–541. doi:10.1016/j.eururo.2014.03.003 CrossRefPubMed

38.

Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E et al (2013) Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 112:453–461. doi:10.1111/j.1464-410X.2012.11649.x CrossRefPubMed

39.

Oudard S, Culine S, Vano Y, Goldwasser F, Théodore C, Nguyen T et al (2015) Multicentre randomised phase II trial of gemcitabine + platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer 51:45–54. doi:10.1016/j.ejca.2014.10.009 CrossRefPubMed

40.

Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS et al (2016) Complete and durable remission of human epidermal growth factor receptor 2-positive metastatic urothelial carcinoma following third-line treatment with trastuzumab and gemcitabine. Urol Int. doi:10.1159/000443280 PubMed

41.

Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M et al (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189:1214–1221. doi:10.1016/j.juro.2012.05.079 CrossRefPubMed

42.

Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK et al (2012) Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 19:4337–4344. doi:10.1245/s10434-012-2499-8 CrossRefPubMedPubMedCentral

Title: HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)
Authors: Francesco Soria
Marco Moschini
Andrea Haitel
Gregory J. Wirth
Jose A. Karam
Christopher G. Wood
Morgan Rouprêt
Vitaly Margulis
Pierre I. Karakiewicz
Alberto Briganti
Jay D. Raman
Solene-Florence Kammerer-Jacquet
Romain Mathieu
Karim Bensalah
Yair Lotan
Mehmet Özsoy
Mesut Remzi
Kilian M. Gust
Shahrokh F. Shariat
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1871-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Assessing the effects of modality of surgery on postoperative weight loss in patients undergoing partial nephrectomy

Prospective assessment of perioperative course in 2648 patients after surgical treatment of benign prostatic obstruction

Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry

Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative